Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Jubilant Pharmova Limited

NSE: JUBLPHARMAPharmaceuticals

Share price

₹932.20

-4.35% close of 8 Oct 2026

Market cap ₹14,915 CrP/E 38.4

Business score

How strong the business is, in one number. The parts behind it are in Pro.

61

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹14,915 Cr

P/E ratio

38.4

P/B ratio

2.1

ROCE

9.0%

ROE

6.5%

Dividend yield

0.5%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹1,181.2052-week low ₹807.65

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 16.3% over the past year, and 6.8% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 16.2% to 14.2% over the last four years.

Whether it grew faster than its sector

It grew 6.8% a year against a sector median of 13.1% — 6.2 percentage points slower.

Room to re-rate, or risk of de-rating

At 38.4× earnings it costs 1.6× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 34.2×, the 72nd percentile of its own range.

Whether growth justifies the valuation

Priced at 0.8 times its growth rate, on earnings growth of 47%.

Profit growthPrice per ₹1 profitPer 1% growth
Jubilant Pharmova Limited — this one47%/yr38.4×₹0.82
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 91 of 130 on returns, 92 of 127 on growth, 80 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 9.0% on capital, ahead of 30% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Roughly — Over the last five years it made ₹4769 crore of cash from the business and spent about as much on plant and equipment. And the profit is real: of every 100 rupees it reported over 12 years, about 248 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back faster than it used to: it went from being waiting 56 days for its cash to waiting 13 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 9 checks clear · 67%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue grew 17.3% year on year, while net profit fell 44.7%.

Announced 10 Aug 2026 · Consolidated · Unaudited

Revenue

₹2,229 Cr

Revenue vs last year

+17.3%

Revenue vs last quarter

-2.6%

Net profit

₹56 Cr

Profit vs last year

-44.7%

Profit vs last quarter

-52.6%

Net margin

2.5%

EPS

₹3.57

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹14,915 Cr
Prev close
₹932.20
52w High
₹1,185
52w Low
₹786
Enterprise value
₹17,262 Cr
Beta
0.7
Price CAGR 1y
-10.0%
Price CAGR 3y
32.0%
Price CAGR 5y
9.0%
Price CAGR 10y
5.0%

Ratios

Return on assets
2.6%
PEG ratio
0.8
P/E ratio
38.4
P/B ratio
2.1
EV / EBITDA
14.2
Industry P/E
38.0
ROCE
9.0%
ROCE 5y average
7.8%
ROE
6.5%
Debt / Equity
0.5
Interest coverage
3.9
Dividend yield
0.5%
ROE 3y average
5.0%
ROE last year
7.0%

Annual P&L

Annual revenue
₹8,280 Cr
Annual profit
₹398 Cr
Operating margin
15.0%
Net profit margin
4.8%
EBITDA margin
15.2%
Sales growth 3y
9.6%
Sales growth 5y
6.3%
Profit growth 3y
47.0%
Profit growth 5y
-13.0%
EPS
₹25.0
Sales growth TTM
16.0%
Profit growth TTM
-20.0%
Dividend payout
20.0%

Quarter P&L

Sales latest quarter
₹2,229 Cr
Profit latest quarter
₹56 Cr
YoY quarterly sales growth
17.3%
YoY quarterly profit growth
-45.1%
OPM latest quarter
11.1%

Balance Sheet

Book Value
₹443
Face Value
₹1.0
Total debt
₹3,615 Cr
Total cash
₹1,268 Cr
Borrowings
₹3,615 Cr
Reserves / Equity
442.3

Cash Flow

Operating cash flow
₹1,227 Cr
Free cash flow
-₹120 Cr
FCF yield
-2.2%
Net cash flow
₹179 Cr

Shareholding

Promoter holding
47.7%
FII holding
15.9%
DII holding
12.4%
Public holding
23.5%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Jubilant Pharmo974.6040.015,5250.5156.4-45.12,229.417.39.0
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,5871,6801,6771,7591,7321,7521,8221,9291,9011,9662,1232,2902,229
Expenses1,4191,4381,4591,4871,4801,4631,5351,5841,6111,6251,8331,9511,981
Material Cost584521565592643638
Change in Inventories-4325-4242-1424
Purchases of Stock-in-Trade857374828587
Employee Cost591591636706767754
Other Expenses367402392410471479
Operating Profit168242218271252289287345290341289339248
OPM %11141315151716181517141511
Other Income91949-1514108-109124-191020
Exceptional items (within Other Income)-3.300-5.80-40-140
Interest62667173716156534950565654
Depreciation9097951019191919598105121117127
Profit before tax2598101-545001441302061541909317686
Tax %7637341542923273437403235
Net Profit66266-624821021011511021205611956
EPS in Rs0.403.924.19-3.68306.456.339.646.467.553.517.503.55
Diluted EPS in Rs9.686.477.573.527.523.56

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5,7515,7495,8617,5189,1115,9766,0996,1306,2826,7037,2358,2808,608
Expenses5,1414,4934,5105,9957,3674,4284,6954,9805,5035,8026,0617,0207,390
Material Cost1,9852,320
Change in Inventories3511
Purchases of Stock-in-Trade297313
Employee Cost2,2682,701
Other Expenses1,4761,675
Operating Profit6101,2561,3521,5221,7441,5481,4031,1507799011,1731,2601,218
OPM %11222320192623191213161514
Other Income8641936-2492252638-9-76416715
Exceptional items (within Other Income)360-59
Interest368371341284220200184145188272240212217
Depreciation288347291415371340349382554382369440470
Profit before tax405427388599041,2331,13363028170981614546
Tax %20029222636272634333571535
Net Profit-40387575634577898836413-6573836398351
EPS in Rs-3.6325364036565226-3.834.84532522
Diluted EPS in Rs5325
Dividend Payout %-8312871291019-130102920

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
4%
5 years
6%
3 years
10%
TTM
16%

Compounded profit growth

10 years
1%
5 years
-13%
3 years
47%
TTM
-20%

Stock price CAGR

10 years
5%
5 years
9%
3 years
32%
1 year
-10%

Return on equity

10 years
9%
5 years
3%
3 years
5%
Last year
7%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161616161616161616161616
Reserves2,4382,9513,4204,0714,7935,5884,7265,3035,3835,4186,2397,077
Borrowings4,7934,4934,0453,4694,8404,8082,8303,1923,6773,6642,7313,615
Other Liabilities1,3721,2801,4171,9021,6701,8981,1921,3191,8532,2403,5984,564
Minority Interest-162.80
Total Liabilities8,6198,7408,8999,45711,31912,3108,7639,83010,92911,33812,58415,272
Fixed Assets4,9115,1045,1075,4015,6486,3404,6094,8715,1835,0915,1766,966
CWIP5976116846719017688971,0901,5622,1033,6304,040
Investments408510312411569241239256424461
Other Assets3,0712,9393,0063,2624,6545,1333,0173,6313,9284,1013,7354,205
Total Assets8,6198,7408,8999,45711,31912,3108,7639,83010,92911,33812,58415,272

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity7831,0991,2681,3031,1221,5431,7848386619711,0721,227
Cash from Investing Activity-362-309-465-614-1,018-267-727-323-474-596512-1,143
Cash from Financing Activity-503-843-686-901657-1,050-1,709-33-157-432-1,45395
Net Cash Flow-82-52117-212761225-65248230-58132179
Free Cash Flow4347608068194739751,270241-13583-38-120

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days526063555179495556504547
Inventory Days169207223177147463268308268220178170
Days Payable99106137145106273124139160146158170
Cash Conversion Cycle12216214987922681942241651246547
Working Capital Days12450454562745657561613
ROCE %61315151615121037109

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters515151515151514848484848
FIIs232019201817171717161616
DIIs1.642.893.774.065.666.997.059.5211111212
Public242626252525242525252424
Others0.590.580.580.580.560.560.560.560.630.570.560.55
No. of Shareholders89,37686,58892,26481,99289,4561,02,44296,52699,67393,33690,13386,34782,703

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -15.1% (₹1,098.00 → ₹932.20)Brick size ₹36.92 (fixed)Bricks 23
₹900₹1,000₹1,100₹932Nov '25Mar '26Jul '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹932.20 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

2,347inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

1,46,36,733inr

2026-03-31

News

News and filings about Jubilant Pharmova Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • API raw materials, Key Starting Materials (KSMs) & intermediates
  • Allergenic source materials
  • Medical radioisotopes (Molybdenum-99 / Technetium-99m)
  • Solvents
  • Stores, spares & packing materials

Buys from

Sells to

  • US Government (BARDA / JPEO-CBRND / HHS / DOD) · sterile fill-finish manufacturing of vaccines & medical countermeasures at Spokane

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE700A01033

Business segments

  • Radiopharma · 44%
  • Contract Development and Manufacturing Organisation - Sterile Injectables · 22%
  • Contract Research, Development and Manufacturing Organisation · 15%
  • Allergy Immunotherapy · 10%
  • Generics · 9%
  • Unallocable corporate · 1%

Plants

  • Jubilant Biosys Bengaluru research center
  • Jubilant Biosys Noida research center
  • Jubilant Cadista Salisbury facility
  • Jubilant DraxImage / HollisterStier Montreal facility
  • Jubilant HollisterStier Spokane facility
  • Nanjangud API facility (Jubilant Generics)
  • Roorkee generics facility (Jubilant Generics)

News impact

Big market events that reach Jubilant Pharmova Limited, and how the effect spreads.

Who it hits first

  • Sterile-injectable makers (Gland, Aurobindo, Lupin, Caplin, Shilpa) face new licensing layer
  • Small job-work sterile units face consolidation pressure
  • CDSCO capacity becomes the approval bottleneck

Who may gain

  • Large compliant players gain share as small units exit
  • Testing and validation service firms gain business

Along the supply chain

Downstream

Hospitals pay slightly more for assured-quality injectables.

Upstream

API and vial suppliers see steadier demand from compliant makers.

Where demand moves

Business

Plants undergo central audits; documentation and QA headcount rise; approvals add months to greenfield timelines.

Capital

Money favours large, audit-ready pharma over small sterile job-workers.

How it spreads across sectors

Healthcare

injectable compliance cost rises; consolidation favours leaders

When it plays out

Immediate

Injectable stocks soften on cost headlines.

Medium term

Cleaner industry commands better US/EU pricing power.

Short term

Watch draft rules, timelines and grandfathering clauses.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

24 Jul 2026unspecified₹5
25 Jul 2025unspecified₹5
2 Aug 2024unspecified₹5
10 Aug 2023unspecified₹5
11 Aug 2022unspecified₹5
5 Aug 2021unspecified₹5
4 Feb 2021demerger₹0
9 Mar 2020interim₹5

Splits, bonuses & buybacks

  • daily-prices repair: 10 rows from NSE's archive (replace 2, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.